Estimating Mednax (USA Stocks:MD) price for March 2023.

All Stories . Forecast . 
Gabriel Shpitalnik .  Story
MD Stock  USD 14.13  0.21  1.51%   
Gabriel Shpitalnik
By Gabriel Shpitalnik
Macroaxis Story
Mednax Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 2.99 Billion. The current year Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to grow to about 307 M, whereas Earnings before Tax are forecasted to decline to about 127.2 M. Today's short post will digest Mednax as your potential position. We will discuss the question of why shareholders should continue to be confident in Mednax outlook.
Published over a month ago
View all stories for Mednax | View All Stories
Macroaxis uses a strict editorial review process to publish our stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Vlad Skutelnik

Mednax Inc has a beta of 1.0866. Let's try to break down what Mednax's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mednax will likely underperform. The beta indicator helps investors understand whether Mednax moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Mednax deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Mednax Inc. Regardless of method or technology, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Mednax

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Mednax's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Mednax in the context of predictive analytics.
Hype
Prediction
Details
Intrinsic
Valuation
Details
Naive
Forecast
Details
9 Analysts
Consensus
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Mednax. Your research has to be compared to or analyzed against Mednax's peers to derive any actionable benefits. When done correctly, Mednax's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Mednax Inc.

How important is Mednax's Liquidity

Mednax financial leverage refers to using borrowed capital as a funding source to finance Mednax Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Mednax financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Mednax's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Mednax, but it might be worth checking our own buy vs. sell analysis

Is Mednax valued correctly by the market?

Mednax Inc exhibits very low volatility with skewness of -0.21 and kurtosis of -0.69. However, we advise investors to further study Mednax Inc technical indicators to ensure that all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Mednax's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Mednax's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Returns Breakdown

3.97
Return on Assets
12.04
Return on Investment
Return on Investment12.04
Return on Assets3.97
Return on Equity19.77
Return Capital0.16
Return on Sales0.12

Will Mednax latest surge continue?

The value at risk is down to -3.56 as of today. Mednax Inc exhibits very low volatility with skewness of -0.21 and kurtosis of -0.69. However, we advise investors to further study Mednax Inc technical indicators to ensure that all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Mednax's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Mednax's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Bottom Line On Mednax Inc

Although some other entities within the medical care facilities industry are still a little expensive, even after the recent corrections, Mednax may offer a potential longer-term growth to shareholders. In closing, as of the 17th of February 2023, we believe that at this point, Mednax is overvalued with below average probability of distress within the next 2 years. Our current buy-or-sell advice on the firm is Hold.

Editorial Staff

Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Mednax Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2023 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY